Crescent Biopharma

Crescent Biopharma is a clinical-stage biotechnology company that develops precisely targeted oncology therapeutics, including bispecific antibodies and antibody-drug conjugates. Its lead program is CR-001, a PD-1 x VEGF bispecific antibody for solid tumors. The company's mission is to deliver better outcomes for patients with cancer. It became publicly traded (Nasdaq: CBIO) through a 2025 merger with GlycoMimetics.